Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis.

ABSTRACT:

Aim

To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced ALK-positive NSCLC.

Methods

A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.

Results

13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibit

SUBMITTER: Samaca-Samaca D 

PROVIDER: S-EPMC10242442 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature